Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19.

Julie BoucauRockib UddinCaitlin MarinoJames ReganJames P FlynnManish C ChoudharyGeoffrey ChenAshley M StuckwischJosh MathewsMay Y LiewArshdeep SinghZahra ReynoldsSurabhi L IyerGrace C ChamberlinTammy D VyasJatin M VyasSarah E TurbettJonathan Z LiJacob E LemieuxAmy K BarczakMark J Siedner

Published in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)

We enrolled seven individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Keyphrases

sars cov
coronavirus disease
antiretroviral therapy
hiv infected
combination therapy
depressive symptoms